Last updated on June 2018

XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD).


Brief description of study

This is a Phase II, randomised, multi-centre, double-blind, placebo-controlled proof-of-concept study to assess the safety, tolerability and efficacy of oral Xanamem™ once daily in adult subjects with mild dementia due to AD.

Clinical Study Identifier: TX206445

Contact Investigators or Research Sites near you

Start Over

Jennifer Cavin

NeuroStudies.net, LLC
Decatur, GA USA
  Connect »